Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies [0.03%]
Umut Dişel,Shumei Kato,Aditya Shreenivas et al.
Umut Dişel et al.
Background: High-grade gliomas are associated with dismal outcomes and have devastating neurologic sequelae. Standard-of-care surgery, radiation, and temozolomide yield a median survival of 14-16 months in patients with g...
Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer [0.03%]
有关维莫非尼联合索拉非尼治疗KRAS突变型晚期胰腺癌的II期临床研究
Muhammad Rizwan Khawaja,Gayle Jameson,Derek Cridebring et al.
Muhammad Rizwan Khawaja et al.
Introduction: Prognosis of metastatic pancreatic cancer remains poor. KRAS mutations are common in pancreatic cancer and are an attractive therapeutic target. Based on a next-generation mechanistic dynamic model, we hypot...
Ethan Quach,Farahnoz Sanginova,Anish Cheruku et al.
Ethan Quach et al.
The AXL receptor tyrosine kinase is a transmembrane protein commonly overexpressed in both solid and hematologic malignancies. AXL plays a role in malignant cell growth, survival, proliferation, and adaptive immunity. As such, AXL overexpre...
Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration [0.03%]
具备复制能力和肿瘤特异性的免疫基因载体可在静脉给药后进行转基因交换并导致病毒持久存在
Lee S Rosen,Christian Ottensmeier,Maria Hawkins et al.
Lee S Rosen et al.
Introduction: Enadenotucirev (EnAd) and successor transgene-armed Tumor-Specific Immuno-Gene (T-SIGn) vectors are replication-competent, blood-stable viral vectors that traffic to tumor sites following intravenous (IV) ad...
Khanh Toan Nguyen,Thi Huong Pham,Van Lam Ngo et al.
Khanh Toan Nguyen et al.
Introduction: This study aims to document patient characteristics, treatment modalities, and survival outcomes of patients with lung cancer in Vietnam from 2018 to 2024. ...
Phase 2 Study of Monotherapy with Pembrolizumab for Advanced Adrenocortical Carcinoma [0.03%]
帕博利珠单抗治疗晚期肾上腺癌的Ⅱ期研究
Brenda Chahla,Bettzy Stephen,Juhee Song et al.
Brenda Chahla et al.
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer with suboptimal response to chemotherapy. The role of immunotherapy in ACC management is evolving. ...
Characterizing Inquiries About Novel Cancer Therapies: Findings from the National Cancer Institute's Cancer Information Service [0.03%]
关于新型癌症疗法咨询的特点研究——美国国家癌症研究所癌症信息部的研究成果分析
Robin C Vanderpool,Laura Dwyer,Diane Ng et al.
Robin C Vanderpool et al.
Exceptional Response to Immunotherapy-based Treatment in Compound EGFR-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report [0.03%]
免疫治疗联合治疗复合型EGFR突变寡转移肺肉瘤样癌的应答：一例报告
Ayushi Gianchandani,Darshana Desai,Janani Sambath et al.
Ayushi Gianchandani et al.
Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) with limited treatment options and poor prognosis. EGFR mutations generally respond to tyrosine kinase inhibitors (TKIs)-based targ...
Immunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination Treatment [0.03%]
免疫疗法和靶向疗法在肉瘤治疗中的协同作用：联合治疗的建议与展望
Aleksandra Watson,Gina D&#x;Amato,Emily Jonczak et al.
Aleksandra Watson et al.
The combination of targeted therapies and immunotherapies for advanced and metastatic sarcomas has been proposed owing to the enhanced effect of antiangiogenic therapies on the tumor microenvironment. We found eight studies published to dat...
Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials [0.03%]
循环肿瘤DNA作为早期临床试验受试者选择的预后生物标志物
Sammy Shaya,Okezie Uche-Ikonne,Bedirhan Kilerci et al.
Sammy Shaya et al.
Introduction: Patients with advanced solid tumors may be considered for early phase clinical trials investigating the safety, tolerability, and dosing of experimental therapies. Optimizing participant selection is critica...